The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Provention Bio, Inc. Securities Litigation
May 25, 2021 | Provention Bio Inc. Common Stock NASDAQ: PRVB | Case Status: Filed
Filing Deadline: July 20, 2021
If you purchased a significant amount of shares of Provention Bio Inc. Common Stock (NASDAQ: PRVB), you have certain options. Investors should contact us before July 20, 2021.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Provention Bio Inc. Common Stock
First Identified Complaint
Adam Paxton, et al. v. Provention Bio, Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint||May 21st, 2021|
|2||U.S. District Court Civil Docket||May 21st, 2021|